Biosimilarity: The FDA Perspective by Sarfaraz K. Niazi

Biosimilarity: The FDA Perspective

Sarfaraz K. Niazi

398 pages missing pub info (editions)

nonfiction health medium-paced
Powered by AI (Beta)
Loading...

Description

Summary: The focus of this book is on how the U.S. FDA will approve biosimilar drugs, as learned from recent approvals by the FDA. Understanding the limitations of the statutory limits and non-inferiority testing are presented as tools to obviate...

Read more

Community Reviews

Loading...

Content Warnings

Loading...